By Fineline Cube China-based Lexenpharm late last week announced a strategic partnership with Aptar Pharma, a US-based global manufacturer of consumer dispensing packaging and drug delivery devices. The collaboration focuses on clinical-stage filling services for single-dose nasal spray devices in Greater China, including Mainland China, Hong Kong, Macau, and Taiwan.
Partnership Details
Under the agreement, Lexenpharm will provide GMP-compliant filling facilities, pharmaceutical R&D, and technical support. Aptar will supply internationally certified single-dose filling equipment and devices. By combining their strengths, the partners aim to offer integrated contract development and manufacturing organization (CDMO) services to accelerate the industrialization of single-dose nasal sprays.
Strategic Significance
This collaboration marks another strategic move by Lexenpharm to strengthen industry chain synergies. Earlier this year, in March, Lexenpharm partnered with Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621), further solidifying its position in the pharmaceutical development and manufacturing landscape.-Fineline Info & Tech